CStone Pharmaceuticals discovers and markets precision oncology therapeutics, including the selective RET inhibitor Pralsetinib (GAVRETO®), the PDGFRA‑mutant GIST inhibitor Avapritinib (AYVAKIT®), and the anti‑PD‑L1 antibody Sugemalimab, all approved in China, the US, EU and Hong Kong. The company also advances bispecific, trispecific antibodies and antibody‑drug conjugates through its translational medicine center and collaborates with partners such as Pfizer to accelerate development and global market access.
Funding
$59.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with cancer often lack therapies that precisely target the molecular drivers of their disease, leading to suboptimal outcomes and limited treatment options, especially for rare genetic alterations such as RET fusions or PDGFRA mutations.
Solution
CStone Pharmaceuticals develops and commercializes innovative oncology medicines that address these gaps through precision‑targeted and immuno‑oncology approaches. Its portfolio includes a selective RET inhibitor (Pralsetinib/GAVRETO®), a PDGFRA‑mutant GIST inhibitor (Avapritinib/AYVAKIT®), a fully human anti‑PD‑L1 antibody (Sugemalimab), and next‑generation bispecific and trispecific antibodies (e.g., CS2015, CS2009). The company leverages a robust R&D pipeline spanning antibody‑drug conjugates (ADCs), multi‑specific antibodies, and small‑molecule inhibitors, supported by an internationally‑standardized translational medicine center in Suzhou for rapid clinical development. Strategic collaborations with global partners such as Pfizer accelerate development and market access, while regulatory approvals in China, the United States, the European Union, and Hong Kong enable broad patient reach.
Target Audience
Oncologists, hematologists, and precision‑medicine clinicians seeking FDA‑, NMPA‑, or EMA‑approved targeted therapies for solid tumors and hematologic malignancies, as well as pharmaceutical partners looking for co‑development or licensing opportunities.
Features
- Selective RET inhibitor Pralsetinib (GAVRETO®) approved for RET‑fusion positive NSCLC and thyroid cancers, now listed in China’s national health insurance.
- PDGFRA‑mutant GIST inhibitor Avapritinib (AYVAKIT®) approved in multiple regions for advanced GIST and systemic mastocytosis.
- Fully human anti‑PD‑L1 monoclonal antibody Sugemalimab (舒格利单抗) with FDA breakthrough‑therapy designation and EU approvals for NSCLC.
- Bispecific antibody CS2015 targeting OX40L/TSLP and trispecific antibody CS2009 (PD‑1/VEGF/CTLA‑4) advancing through Phase I/II trials.
- Antibody‑drug conjugate (ADC) platform enabling generation of next‑generation tumor‑targeted cytotoxics.
- Suzhou Translational Medicine Research Center providing GMP‑compliant clinical trial infrastructure and rapid IND filing.
- Global partnership network (e.g., Pfizer, Blueprint Medicines) for co‑development, licensing, and commercialization.
- Comprehensive regulatory portfolio with approvals and submissions across China, US, EU, and Hong Kong, facilitating multi‑regional market entry.